TECregen

TECregen is pioneering the use of thymus rejuvenation technology to address diseases caused by impaired T-cell responses. The company's innovative approach focuses on activating and expanding thymic epithelial cells (TECs) to replenish T-cells and achieve lasting improvements in immune function. By developing a pipeline of differentiating thymus biologics, TECregen aims to enhance immune recovery after transplantation or cytotoxic treatments, promote immune health, strengthen cancer immune surveillance, and usher in a new era of immunotherapy.